Abstracts tagged "Febuxostat"

Abstract Number: 1900 • ACR Convergence 2021
Urate Lowering Therapy in the Treatment of Gout: A Multicenter, Randomized, Double-blind Comparison of Allopurinol and Febuxostat Using a Treat-to-Target Strategy
James O'Dell¹, Tuhina Neogi², Michael Pillinger³, Paul Palevsky⁴, Jeff Newcomb¹, Mary Brophy⁵, Hongsheng Wu⁵, Annie Davis-Karim⁶, Ryan Ferguson⁵, David Pittman⁶, Robert Terkeltaub⁷, Amy Cannella¹, Bryant England¹, Lindsay Helget¹, Ted Mikuls¹ and Tomas Taylor⁸, ¹University of Nebraska Medical Center, Omaha, NE, ²Boston University School of Medicine, Boston, MA, ³New York University Grossman School of Medicine, New York,, NY, ⁴Pittsburgh University, Pittsburgh, PA, ⁵Boston VA, Boston, MA, ⁶Albuquerque VA, Albuquerque, NM, ⁷VA/UCSD, San Diego, CA, ⁸White River Junction VA, White River Junction, VT
Background/Purpose: Urate lowering therapy (ULT) is a cornerstone treatment in the management of gout. A paucity of data exists about the relative efficacy and safety…
Abstract Number: 348 • 2019 ACR/ARP Annual Meeting
Patterns of Newer Gout Medication Use in a U.S. Electronic Health Record-Based Registry
Kenneth Saag¹, Andreas Reimold ², Lang Chen ¹, Huifeng Yun ¹ and Jeffrey Curtis ¹, ¹University of Alabama at Birmingham, Birmingham, AL, ²UT Southwestern Medical Center, Dallas
Background/Purpose: A variety of newer gout therapies have been introduced in recent years, some with potential safety concerns. However, uptake of these therapies and associated…
Abstract Number: 355 • 2019 ACR/ARP Annual Meeting
Comparative Risk of Cardiovascular Events in US Veterans with Gout Treated with Febuxostat versus Allopurinol
Hanna Zembrzuska¹, Yubo Gao ¹, Saket Girotra ¹, Brian Lund ², Kenneth Saag ³, Jeffrey Curtis ³, Mary Vaughan-Sarrazin ² and Namrata Singh ⁴, ¹University of Iowa Hospitals and Clinics, Iowa City, IA, ²Iowa City VA Health Care System, Iowa City, IA, ³University of Alabama at Birmingham, Birmingham, AL, ⁴University of Iowa, Iowa City
Background/Purpose: Gout is the most common inflammatory arthritis and is particularly common among veterans. Recent studies, a randomized controlled trial (CARES, White et al. NEJM…
Abstract Number: 873 • 2018 ACR/ARHP Annual Meeting
General Safety of Febuxostat and Allopurinol in a Cardiovascular Outcomes Study in Patients with Gout
Kenneth Saag¹, Michael A. Becker², William B. White³, Andrew Whelton⁴, Jeffrey Borer⁵, Philip Gorelick⁶, Barbara Hunt⁷, Majin Castillo⁷ and Lhanoo Gunawardhana⁷, ¹University of Alabama at Birmingham, Birmingham, AL, ²University of Chicago Pritzker School of Medicine, Chicago, IL, ³Cardiology, University of Connecticut School of Medicine, Farmington, CT, ⁴Johns Hopkins University School of Medicine, Hunt Valley, MD, ⁵State University of New York Downstate Medical Center, Brooklyn, NY, ⁶Michigan State University College of Human Medicine, Grand Rapids, MI, ⁷Takeda Pharmaceuticals International, Deerfield, IL
Background/Purpose: The cardiovascular (CV) safety study CARES has the longest study duration of any randomized controlled trial in patients (pts) with gout and CV disease.…
Abstract Number: 1128 • 2018 ACR/ARHP Annual Meeting
Impact of Urate-Lowering Therapy on the Risk of Cardiovascular Events and All-Cause Mortality Among Individuals with Gout
In Ah Choi¹, Hoyeon Jang² and Gil-Won Kang², ¹Division of Rheumatology, Department of Internal Medicine, Chungbuk National University Hospital, Cheongju, Korea, Republic of (South), ²Department of Health Informatics and Management, College of Medicine, Chungbuk National University, Cheongju, Korea, Republic of (South)
Background/Purpose: Gout results from an increased body pool of urate that occurs with hyperuricemia. Although urate-lowering therapy (ULT) is beneficial to prevent gout attack, current…
Abstract Number: 1272 • 2018 ACR/ARHP Annual Meeting
Quality of Gout Management in a Rheumatology Clinic Using a Provider-Pharmacist Team-Based Approach
Jessica Michaud¹ and Jenna Beatty², ¹Pharmacy, Froedtert & the Medical College of Wisconsin, Milwaukee, WI, ²University of Kansas, kansas city, MO
Background/Purpose: Gout is the most common form of inflammatory arthritis.1 The cornerstone of treatment for gout is urate-lowering therapy (ULT), which in the U.S. includes…
Abstract Number: 1114 • 2017 ACR/ARHP Annual Meeting
Effects of Diacerein Controlled Release Tablets in Serum Uric Acid Reduction in Treating Subjects with Gout
Ying-Chou Chen Sr.¹, Shih-Chueh Chen², Chung-Tei Chou³, Carl Brown⁴, Jing-Yi Lee⁴, Wei-Shu Lu⁵ and Chang Youh Tsai⁶, ¹Division of Rheumatology, Allergy and Immunology, Department of Internal Medicine, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Kaohsiung County, Taiwan, ²Department of Endocrinology, Cheng Ching General Hospital, Taichung, Taiwan, ³Division of Allergy-Immunology-Rheumatology, Department of Medicine, Taipei Veterans General Hospital, Taipei, Taiwan, ⁴Medical Research, TWi Biotechnology, Inc., Taipei, Taiwan, ⁵TWi Biotechnology, Inc., Taipei, Taiwan, ⁶Division of Allergy- Immunology- Rheumatology, Department of Medicine, Taipei Veterans General Hospital, Taipei, Taiwan
Background/Purpose: The goal of gout treatment is to reduce serum uric acid (sUA) concentrations below the urate solubility limit. Diacerein is known as an oral…
Abstract Number: 2058 • 2017 ACR/ARHP Annual Meeting
A Study on Febuxostat Prescribing Practices for Patients with Chronic Gout Previously Managed with Allopurinol at the Veterans Affairs Puget Sound
Percy Balderia and Elizabeth R. Wahl, Rheumatology, University of Washington School of Medicine, Seattle, WA
Background/Purpose: American College of Rheumatology (ACR) guidelines recommend use of either allopurinol or febuxostat as first-line approaches to urate lowering therapy in gout. Prior studies…
Abstract Number: 195 • 2016 ACR/ARHP Annual Meeting
Pharmacodynamics, Pharmacokinetics, and Safety of Verinurad in Combination with Febuxostat Versus Febuxostat Alone and Verinurad Alone in Japanese Adults with Gout or Asymptomatic Hyperuricemia: A Phase 2a, Open-Label Study
Masanari Shiramoto¹, Masatoshi Sugeno², Sha Liu³, Zangong Shen³ and Jesse Hall³, ¹SOUSEIKAI PS Clinic, Fukuoka, Japan, ²AstraZeneca K.K., Osaka, Japan, ³Ardea Biosciences, Inc., San Diego, CA
Background/Purpose: Verinurad (RDEA3170) is a high-affinity URAT1 inhibitor in development for the treatment of gout and asymptomatic hyperuricemia. This Phase 2a, randomized, open-label, single-site study…
Abstract Number: 197 • 2016 ACR/ARHP Annual Meeting
Pharmacodynamic Effects and Safety of Verinurad in Combination with Febuxostat Versus Febuxostat Alone in Adults with Gout: A Phase 2a, Open-Label Study
Roy Fleischmann¹, Peter Winkle², Jesse Hall³, Shakti Valdez³, Sha Liu³, Xiaohong Yan³, Liz Hicks³ and Martha Hernandez-Illas⁴, ¹Medicine, University of Texas Southwestern Medical Center, Dallas, TX, ²Anaheim Clinical Trials, Anaheim, CT, ³Ardea Biosciences, Inc., San Diego, CA, ⁴QPS MRA (Miami Clinical Research), Miami, FL
Background/Purpose: Verinurad (RDEA3170) is a high-affinity, selective URAT1 inhibitor in development for treatment of gout and asymptomatic hyperuricemia. This Phase 2a, randomized, open-label, multicenter study…
Abstract Number: 207 • 2016 ACR/ARHP Annual Meeting
Integrated Safety of Lesinurad, a Novel Uric Acid Reabsorption Inhibitor for the Treatment of Gout
Michael A. Becker¹, Robert T. Keenan², Puja Khanna³, Raymond Malamet⁴, Kathleen Bos⁴, Jingyi Li⁴, Jia Hu⁵ and William White⁶, ¹University of Chicago, Chicago, IL, ²Rheumatology, Duke University, Durham, NC, ³Rheumatology, University of Michigan, Ann Arbor, MI, ⁴AstraZeneca Pharmaceuticals, Wilmington, DE, ⁵Ardea Biosciences, Inc., San Diego, CA, ⁶University of Connecticut School of Medicine, Farmington, CT
Background/Purpose: Lesinurad is a selective uric acid reabsorption inhibitor recently approved at 200 mg daily in combination with a xanthine oxidase inhibitor (XOI) for treatment…
Abstract Number: 208 • 2016 ACR/ARHP Annual Meeting
Examination of Serum Uric Acid (sUA) Lowering and Safety with Extended Lesinurad + Allopurinol Treatment in Subjects with Gout
Kenneth Saag¹, Michael A. Becker², Chris Storgard³, Maple Fung³, Jia Hu³ and Thomas Bardin⁴, ¹University of Alabama at Birmingham, Birmingham, AL, ²University of Chicago, Chicago, IL, ³Ardea Biosciences, Inc., San Diego, CA, ⁴Hôpital Lariboisière, Paris, France
Background/Purpose: Two replicate, randomized, core Phase III trials (CLEAR 1 & 2) reported significantly more subjects treated with lesinurad 200 mg (LESU200) or 400 mg…
Abstract Number: 209 • 2016 ACR/ARHP Annual Meeting
Clinical Response of Tophus and Flares to Extended Use of Lesinurad in Combination with a Xanthine Oxidase Inhibitor in Patients with Gout
Thomas Bardin¹, Nicola Dalbeth², Robert Terkeltaub³, Chris Storgard⁴, Maple Fung⁴, Jia Hu⁴ and Fernando Perez-Ruiz⁵, ¹Hôpital Lariboisière, Paris, France, ²University of Auckland, Auckland, New Zealand, ³Medicine-Rheumatology, VA Medical Ctr/University of California San Diego, San Diego, CA, ⁴Ardea Biosciences, Inc., San Diego, CA, ⁵Hospital de Cruces and Biocruces Health Research Institute, Vizcaya, Spain
Background/Purpose: Three randomized, double-blind, Phase III trials reported that greater proportions of patients treated with lesinurad 200 mg (LESU200) or 400 mg (LESU400), combined with…
Abstract Number: 211 • 2016 ACR/ARHP Annual Meeting
Safety and Efficacy of Febuxostat in Advanced CKD Patients with Hyperuricemia
Yoon-Jeong Oh¹, Seung Min Jung¹, Sang-Won Lee², Yong-Beom Park² and Jason Jungsik Song², ¹Division of Rheumatology, Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea, The Republic of, ²Division of Rheumatology, Department of Internal Medicine, Yonsei University College of Medicine, Seoul, South Korea
Background/Purpose: Dosing adjustments and increased risk of serious side effects of uric acid lowering agents in patients with reduced renal function lead to undercorrection of…
Abstract Number: 3128 • 2016 ACR/ARHP Annual Meeting
A Longitudinal Dual Energy Computed Tomography Study on the Effect of Urate Lowering Therapies on the Reduction of Tophus Burden in Patients with Chronic Gout
Hanna Ellmann¹, Sara Bayat¹, Isabelle Oliveira¹, Matthias Englbrecht^2,3, Elizabeth Araujo⁴, Alexander Cavallaro⁵, Silvana Mendonca⁶, Michael Lell⁵, Bernhard Manger², Georg Schett⁷ and Juergen Rech⁷, ¹Medical Department 3, Rheumatology & Clinical Immunology, Friedrich-Alexander-University Erlangen-Nürnberg (FAU), Erlangen, Germany, ²Department of Internal Medicine 3, Rheumatology & Clinical Immunology, Friedrich-Alexander-University Erlangen-Nürnberg (FAU), Erlangen, Germany, ³Department of Internal Medicine 3, University of Erlangen-Nuremberg, Erlangen, Germany, ⁴Medical Department 3; Rheumatology & Clinical Immunology, Friedrich-Alexander-University Erlangen-Nürnberg (FAU), Erlangen, Germany, ⁵Department of Radiology, University of Erlangen-Nuremberg, Department of Radiology, Erlangen, Germany, ⁶Americas Medical City, Rio de Janeiro, Brazil, ⁷Department of Internal Medicine 3 – Rheumatology and Immunology, Universitätsklinikum Erlangen, Friedrich-Alexander-University Erlangen-Nürnberg (FAU), Erlangen, Germany
Background/Purpose: Dual energy computed tomography (DECT) allows reliably detecting and quantifying tophus burden in patients with chronic gout. Longitudinal studies on the effect of uric…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].